Entry Point Capital, LLC Intellia Therapeutics, Inc. Transaction History
Entry Point Capital, LLC
- $68.4 Billion
- Q2 2024
A detailed history of Entry Point Capital, LLC transactions in Intellia Therapeutics, Inc. stock. As of the latest transaction made, Entry Point Capital, LLC holds 322 shares of NTLA stock, worth $5,152. This represents 0.01% of its overall portfolio holdings.
Number of Shares
322
Previous 4,122
92.19%
Holding current value
$5,152
Previous $113 Million
93.65%
% of portfolio
0.01%
Previous 0.1%
Shares
3 transactions
Others Institutions Holding NTLA
# of Institutions
318Shares Held
88.5MCall Options Held
668KPut Options Held
865K-
Cathie Wood Ark Investment Management LLC | St. Petersburg, Fl12.3MShares$196 Million2.39% of portfolio
-
Black Rock Inc. New York, NY9.6MShares$154 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA9.1MShares$146 Million0.0% of portfolio
-
Deep Track Capital, LP Greenwich, CT4.8MShares$76.8 Million3.53% of portfolio
-
State Street Corp Boston, MA4.36MShares$69.8 Million0.0% of portfolio
About Intellia Therapeutics, Inc.
- Ticker NTLA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 76,011,800
- Market Cap $1.22B
- Description
- Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemoph...